A via de sinalização da GTPase RhoA atua em diversos processos celulares. Para avaliar o comportamento de RhoA, após estresse causado por radiação ultravioleta, foram gerados clones mutantes que expressam RhoA em seu estado constitutivamente ativo e dominante negativo. Após exposição das linhagens à radiação ultravioleta, observou-se uma maior sensibilidade e um maior tempo de recuperação das linhagens quando a atividade de RhoA é reduzida. Estes prejuízos no reparo prejudicaram a proliferação e sobrevivência celular quando da deficiência na atividade de RhoA. Em linhagens deficientes na via de NER, percebemos que estas linhagens possuem uma capacidade ainda mais reduzida de reparo quando a atividade de RhoA é inibida. / The RhoA GTPase signaling pathway acts on many cellular processes. To evaluate this possible RhoA function after stress caused by ultraviolet radiation, mutant clones expressing RhoA in its constitutively active or dominant negative forms were generated. After exposure of the cells to ultraviolet radiation, cell lines showed a higher sensitivity and a delayed recovery capacity when the RhoA activity is reduced. The impaired repair reduced the cells proliferation and survival under RhoA deficiency. In cell lines deficient in NER pathway, we notice that these cell lines, have a further reduced ability to repair damaged DNA under RhoA inhibition.

Les protéoglycanes (PGs) jouent un rôle essentiel dans plusieurs processus physiologiques majeurs tels que la signalisation cellulaire, la prolifération et la migration ; ceci grâce aux interactions entre leurs chaînes de glycosaminoglycanes (GAGs) avec des médiateurs solubles et leurs récepteurs. L'initiation de la synthèse des chaînes de GAGs des PGs est catalysée par la xylosyltransferase I (XT-I). Récemment plusieurs études ont montré différentes mutations au niveau du gène de la XT-I associées au syndrome Desbuquois de type II, caractérisée des anomalies ostéoarticulaires. Afin d’étudier le rôle de la XT-I dans le développement ostéoarticulaire, nous avons généré des souris invalidées pour le gène de la XT-I (XT-I KO). L'analyse morphologique des embryons montre que les souris XT-I KO présentent un nanisme prononcé et une hypoplasie frontonasale apparente, indiquant des anomalies du développement ostéoarticulaire. L'évaluation du contenu en PGs a révélé une forte diminution de la synthèse des PGs chez les souris XT-I KO. L'examen des différentes zones chondrocytaires au niveau de la plaque de croissance des os longs a révélé la perte de l’organisation en colonne des chondrocytes prolifératifs et une réduction importante de la zone hypertrophique. Afin d'identifier les mécanismes et les facteurs à l’origine des anomalies squelettiques chez les souris XT-I KO, l'expression de plusieurs gènes impliqués dans le développement du squelette et dans la régulation de la chondrogenèse a été analysée par hybridation in situ à l'aide de la technique RNAscope. Les résultats ont montré une forte expression des marqueurs de l’hypertrophie chondrocytaires suggérant ainsi une maturation précoce des chondrocytes chez les souris XT-I KO. Les embryons XT-I KO montrent également une formation précoce du centre d'ossification secondaire, indiquant une ossification précoce qui participerait aux anomalies de croissance observées chez les souris XT-I KO. L’étude des voies de signalisation impliquées dans la différenciation et la maturation chondrocytaire a révélé une surexpression du récepteur FGFR3 et une activation importante de la signalisation sous-jacente, suggérant ainsi des perturbations de la signalisation du FGF. Compte tenu du rôle important du FGFR3 dans la régulation de la chondrogenèse et de l’ossification endochondrale, ces résultats suggèrent fortement l’implication de la voie de FGF dans le développement des anomalies squelettiques chez les souris XT-I KO et ouvrent la voie pour le développement de de nouvelles thérapeutiques pour le traitement des patients atteints du syndrome Desbuquois de type II. / Proteoglycans (PGs) play an essential role in several major physiological processes such as cell signaling, proliferation and migration; this is mainly due to the interactions between their glycosaminoglycan chains (GAGs) with soluble mediators and their receptors. The initiation of the synthesis of GAG chains of PGs is catalyzed by Xylosyltransferase I (XT-I). Recently several studies have shown that mutations in XT-I gene are associated with Desbuquois syndrome type II which is characterized by skeletal abnormalities. To study the role of XT-I in skeletal development, we generated knockout mice for the XT-I gene (XT-I KO). XT-I KO mice show pronounced dwarfism and apparent frontonasal hypoplasia reflecting abnormalities in skeletal development. Evaluation of PG content revealed a strong decrease in PG synthesis in XT-I KO mice. Analysis of the different chondrocyte zones in the growth plate revealed a loss of columnar organization of proliferative chondrocyte and a significant reduction of the hypertrophic zone. To identify the mechanisms and factors underlying skeletal abnormalities in XT-I KO mice, the expression of several genes involved in skeletal development and in the regulation of chondrogenesis were analyzed by in situ hybridization using RNAscope technique. The results showed a strong expression of markers of chondrocyte hypertrophy thus suggesting early maturation of chondrocytes in XT-I KO mice. The XT-I KO embryos show also a premature formation of the secondary ossification center, indicating a precocious ossification which ultimately leads to the growth abnormalities showed in XT-I KO mice. The study of the signaling pathways involved in differentiation and chondrocyte maturation revealed an overexpression of the FGFR3 receptor and a significant activation of the downstream signaling pathways, thus suggesting disturbances of FGF signaling. Given the important role of FGFR3 in the regulation of chondrogenesis and endochondral ossification, these results strongly suggest the involvement of the FGF pathway in the development of skeletal abnormalities in XT-I KO mice and pave the way for the development of new therapeutics for the treatment of patients with Desbuquois syndrome type II.

Ubiquitylation is an indispensable post-translational modification system in eukaryotic cells that leads to the covalent attachment of a small ubiquitin (Ub) protein onto a target. The traditional and best-characterized role for ubiquitylation is a fundamental regulatory mechanism whereby target proteins are tagged with a characteristic Lys48-linked Ub chain that signals for their elimination through proteasomal degradation. Challenging this conventional wisdom is the finding that some ubiquitylated proteins are modified by Ub chains linked through Lys63, providing a molecular signal that is thought to be structurally and functionally distinct from Lys48-linked Ub chains. Of further interest and significance is that the Lys63-linked Ub chains are apparently synthesized through a novel biochemical mechanism employing a unique complex formed between a true Ub conjugating enzyme (E2), Ubc13, and an E2-variant (Uev), Mms2 (or Uev1A). The goal of this thesis was to employ structural and functional approaches in order to better characterize the Ubc13-Mms2 Lys63-linked Ub conjugation complex. <p>Error-free DNA damage tolerance (DDT) in the budding yeast is dependent on Lys63-linked Ub chains synthesized by Ubc13-Mms2 and thus provided the opportunity to experimentally test the function of the human UBC13 and MMS2 genes in a simple model organism. Human UBC13 and MMS2 were each shown to function in place of their yeast counterparts and in accordance, human Ubc13 was shown to physically interact with yeast Mms2, and vice versa. Two human MMS2 homologs were also tested and it was determined that UEV1A but not UEV1B can function in place of mms2 in yeast DDT. Physical interactions were observed between Ubc13 and Uev1A, but not between Ubc13 and Uev1B, suggesting that Ubc13-Uev complex formation is required for function. <p>In collaboration with a research group at the University of Alberta, crystal structure and NMR data were used to develop a mechanistic model for the conjugation of Lys63-linked Ub chains by the Ubc13-Mms2 heterodimer, whereby the special orientation of two Ub molecules facilitates a specific Ub-Ub linkage via Lys63. In order to help support the in vitro model and to determine how the Ubc13-Mms2 structure relates to biological function, I used a structure-based approach to direct the creation of point mutations within four key regions of the Ubc13-Mms2 heterodimer; the Ubc13 active-site, the Ubc13-E3 (Ub ligating enzyme) interface, the Mms2-Ub interface, and the Ubc13-Mms2 interface. <p>Underscoring the importance of the Ub conjugation by Ubc13-Mms2, a Ubc13-C87S active-site mutation was created that could bind to Mms2 but was unable to function in DDT. Regarding the Ubc13-E3 interface, a single Ubc13-M64A point mutation had a potent effect on disrupting Ubc13 function in DDT, as well as its physical interaction with Rad5, TRAF6, and CHFR. The results suggest that different RING finger E3s use the same Ubc13 surface to sequester the Ub conjugation activity of Ubc13-Mms2. Two human Mms2 mutations at Ser32 and Ile62, which are contained within the Mms2-Ub interface, were found to reduce the ability of Mms2 to bind Ub. When the corresponding yeast mutations are combined, a synergistic loss in DDT function is observed. The relative orientation of Ser32 and Ile62 suggests that the Mms2 and Tsg101 Uev families use different Uev surfaces to physically interact with Ub. A 200 ìM dissociation constant for the wild-type Mms2-Ub interaction was also determined. The systematic mutagenesis and testing of 14 Ubc13-Mms2 interface residues led to mutants with partial or complete disruption of binding and function. Using this data, a model involving the insertion of a specific Mms2-Phe residue into a unique Ubc13 hydrophobic pocket was created to explain the specificity of Mms2 for Ubc13, and not other E2s. In addition, the dissociation constant for the wild-type Ubc13-Mms2 heterodimer was determined to be approximately 50 nM. <p>The structural and functional studies strongly support the notion that Ubc13-Mms2 complex has the unique ability to conjugate Lys63-linked Ub chains. However, several reported instances of Lys63-linked Ub chains in vivo have not yet been attributed to Ubc13 or Mms2. To address the disparity I was able to demonstrate and map a physical interaction between Mms2 and Rsp5, an E3 implicated in Lys63-linked Ub conjugation. Surprisingly, it was found that MMS2 is not responsible for the RSP5-dependent Lys63-linked Ub conjugation of a plasma membrane protein. A possible explanation for the apparent paradox is presented.

Signaling pathways are complex and function to transmit signals from the extracellular environment into the cell. Analysis of results obtained from a high throughput siRNA screen led to the identification of Membrane protein palmitoylated 3 (MPP3) and Leukocyte Tyrosine Kinase (LTK) as novel negative regulators of the Wnt pathway. MPP3 is a MAGUK family protein and domain mapping studies indicated that the Guk domain plays a role in the negative regulation of the pathway. LTK, a receptor tyrosine kinase, has several transcript variants one of which lacks the entire kinase domain (LTK∆KD). While LTK∆KD interacted with the Wnt receptor Frizzled7, the full length LTK did not, suggesting distinct modes of pathway regulation. Analysis of neuronal cells, NIE115 and Neuro2a, demonstrated LTK is expressed and that cells are Wnt3a responsive, thereby providing a neuronal model system appropriate for further studies on the mechanism and biological role of LTK as a negative regulator of the Wnt pathway

Signaling pathways are complex and function to transmit signals from the extracellular environment into the cell. Analysis of results obtained from a high throughput siRNA screen led to the identification of Membrane protein palmitoylated 3 (MPP3) and Leukocyte Tyrosine Kinase (LTK) as novel negative regulators of the Wnt pathway. MPP3 is a MAGUK family protein and domain mapping studies indicated that the Guk domain plays a role in the negative regulation of the pathway. LTK, a receptor tyrosine kinase, has several transcript variants one of which lacks the entire kinase domain (LTK∆KD). While LTK∆KD interacted with the Wnt receptor Frizzled7, the full length LTK did not, suggesting distinct modes of pathway regulation. Analysis of neuronal cells, NIE115 and Neuro2a, demonstrated LTK is expressed and that cells are Wnt3a responsive, thereby providing a neuronal model system appropriate for further studies on the mechanism and biological role of LTK as a negative regulator of the Wnt pathway

Ubiquitylation is an indispensable post-translational modification system in eukaryotic cells that leads to the covalent attachment of a small ubiquitin (Ub) protein onto a target. The traditional and best-characterized role for ubiquitylation is a fundamental regulatory mechanism whereby target proteins are tagged with a characteristic Lys48-linked Ub chain that signals for their elimination through proteasomal degradation. Challenging this conventional wisdom is the finding that some ubiquitylated proteins are modified by Ub chains linked through Lys63, providing a molecular signal that is thought to be structurally and functionally distinct from Lys48-linked Ub chains. Of further interest and significance is that the Lys63-linked Ub chains are apparently synthesized through a novel biochemical mechanism employing a unique complex formed between a true Ub conjugating enzyme (E2), Ubc13, and an E2-variant (Uev), Mms2 (or Uev1A). The goal of this thesis was to employ structural and functional approaches in order to better characterize the Ubc13-Mms2 Lys63-linked Ub conjugation complex. <p>Error-free DNA damage tolerance (DDT) in the budding yeast is dependent on Lys63-linked Ub chains synthesized by Ubc13-Mms2 and thus provided the opportunity to experimentally test the function of the human UBC13 and MMS2 genes in a simple model organism. Human UBC13 and MMS2 were each shown to function in place of their yeast counterparts and in accordance, human Ubc13 was shown to physically interact with yeast Mms2, and vice versa. Two human MMS2 homologs were also tested and it was determined that UEV1A but not UEV1B can function in place of mms2 in yeast DDT. Physical interactions were observed between Ubc13 and Uev1A, but not between Ubc13 and Uev1B, suggesting that Ubc13-Uev complex formation is required for function. <p>In collaboration with a research group at the University of Alberta, crystal structure and NMR data were used to develop a mechanistic model for the conjugation of Lys63-linked Ub chains by the Ubc13-Mms2 heterodimer, whereby the special orientation of two Ub molecules facilitates a specific Ub-Ub linkage via Lys63. In order to help support the in vitro model and to determine how the Ubc13-Mms2 structure relates to biological function, I used a structure-based approach to direct the creation of point mutations within four key regions of the Ubc13-Mms2 heterodimer; the Ubc13 active-site, the Ubc13-E3 (Ub ligating enzyme) interface, the Mms2-Ub interface, and the Ubc13-Mms2 interface. <p>Underscoring the importance of the Ub conjugation by Ubc13-Mms2, a Ubc13-C87S active-site mutation was created that could bind to Mms2 but was unable to function in DDT. Regarding the Ubc13-E3 interface, a single Ubc13-M64A point mutation had a potent effect on disrupting Ubc13 function in DDT, as well as its physical interaction with Rad5, TRAF6, and CHFR. The results suggest that different RING finger E3s use the same Ubc13 surface to sequester the Ub conjugation activity of Ubc13-Mms2. Two human Mms2 mutations at Ser32 and Ile62, which are contained within the Mms2-Ub interface, were found to reduce the ability of Mms2 to bind Ub. When the corresponding yeast mutations are combined, a synergistic loss in DDT function is observed. The relative orientation of Ser32 and Ile62 suggests that the Mms2 and Tsg101 Uev families use different Uev surfaces to physically interact with Ub. A 200 ìM dissociation constant for the wild-type Mms2-Ub interaction was also determined. The systematic mutagenesis and testing of 14 Ubc13-Mms2 interface residues led to mutants with partial or complete disruption of binding and function. Using this data, a model involving the insertion of a specific Mms2-Phe residue into a unique Ubc13 hydrophobic pocket was created to explain the specificity of Mms2 for Ubc13, and not other E2s. In addition, the dissociation constant for the wild-type Ubc13-Mms2 heterodimer was determined to be approximately 50 nM. <p>The structural and functional studies strongly support the notion that Ubc13-Mms2 complex has the unique ability to conjugate Lys63-linked Ub chains. However, several reported instances of Lys63-linked Ub chains in vivo have not yet been attributed to Ubc13 or Mms2. To address the disparity I was able to demonstrate and map a physical interaction between Mms2 and Rsp5, an E3 implicated in Lys63-linked Ub conjugation. Surprisingly, it was found that MMS2 is not responsible for the RSP5-dependent Lys63-linked Ub conjugation of a plasma membrane protein. A possible explanation for the apparent paradox is presented.

Depuis la découverte de la première protéine possédant une activité tyrosine kinase (protein tyrosine kinase [PTK]) dans les années 1980, l’importance des PTKs et de la phosphorylation sur résidu tyrosine dans la régulation des événements de signalisation intracellulaire est bien établie. Quant aux protéines qui possèdent une activité tyrosine phosphatase (protein tyrosine phosphatase [PTP]), dont l’existence n’a été dévoilée qu’une dixaine d’années plus tard, elles ont longtemps été perçues comme des enzymes dont le rôle ne se résumait qu'à contrecarrer passivement les activités des PTKs. Il est maintenant clair que les activités des PTPs sont spécifiques, hautement régulées, et qu’elles doivent être coordonnées avec celles des PTKs pour une régulation adéquate des événements de signalisation intracellulaire. En dépit de cette évidence, la contribution des PTPs à la régulation des différents processus physiologiques fondamentaux demeure encore peu caractérisée. C’est le cas, notamment, de l’angiogenèse, le processus par lequel de nouveaux vaisseaux sanguins sont formés à partir de ceux préexistants. Le VEGF (Vascular endothelial growth factor), un des facteurs angiogéniques les plus importants, est connu pour induire majoritairement ses effets biologiques via l’activation du récepteur à activité tyrosine kinase VEGFR2 (Vascular endothelial growth factor receptor 2). Puisque l’angiogenèse est impliquée dans le développement d’une multitude de pathologies, dont la progression tumorale, une meilleure caractérisation des PTPs qui assurent la qualité de la réponse angiogénique en agissant de pair avec le VEGFR2 s’avère cruciale et ce, afin de raffiner les outils thérapeutiques actuels. L’expression de la PTP DEP-1 corrèle avec la déphosphorylation du récepteur VEGFR2 localisé au niveau des jonctions cellules-cellules et contribue à l’inhibition de la prolifération des cellules endothéliales en réponse au VEGF lorsque les cellules sont à confluence. Par contre, la contribution spécifique de DEP-1 à la régulation des voies de signalisation et des réponses biologiques induites par le VEGF demeurait toujours inconnue. Les travaux de recherche présentés dans cette thèse démontrent tout d’abord que DEP-1 régule négativement l’activité tyrosine kinase de VEGFR2 en déphosphorylant spécifiquement les résidus tyrosine Y1054/Y1059 de sa boucle d’activation. Cette déphosphorylation mène par conséquent à une diminution générale de la phosphorylation du récepteur et à une atténuation de la plupart des voies de signalisation induites par le VEGF, incluant la voie mitogénique PLCγ-ERK1/2. Par ailleurs, malgré ce rôle négatif global, nos travaux révèlent étonnement, et pour la première fois, que DEP-1 contribue d’une manière positive à la promotion de la survie des cellules endothéliales via l’activation de la voie Src-Gab1-Akt en aval du récepteur VEGFR2. Ce pouvoir pro-survie de DEP-1 dans les cellules endothéliales réside avant tout dans sa capactié à déphosphoryler la tyrosine inhibitrice de Src (Y529). Au cours de notre étude, nous avons pu identifier deux résidus tyrosine au niveau de l’extrémité carboxy-terminale de DEP-1, Y1311 et Y1320, dont la phosphorylation est dépendante de Src. Nos travaux révèlent par ailleurs que ces deux résidus tyrosine phosphorylés lient le domaine SH2 de Src et que la Y1320 est principalement requise pour l’activation de Src et d’Akt en réponse au VEGF dans les cellules endothéliales. Ces résultats constituent donc une avancée majeure dans la compréhension des mécanismes moléculaires par lesquels DEP-1 peut réguler le programme angiogénique dépendant du VEGF. De plus, cette découverte d’un rôle positif pour DEP-1 dans la survie des cellules endothéliales pourrait mener à l’élaboration de nouvelles approches thérapeutiques visant à inhiber cette fonction spécifique de DEP-1 pour bloquer l'angiogenèse pathologique. / Since the discovery of the first protein tyrosine kinase [PTK] in 1980, the importance of these proteins and of tyrosine phosphorylation cascades in the regulation of intracellular signaling events has been well-established. The protein tyrosine phosphatases [PTPs], whose existence was only revealed ten years later, have been regarded for a long time as passive PTKs conteracting enzymes. It is now evident that PTPs activities are specific, exquisitely regulated, and that they have to be coordinated with PTKs activities for an appropriate regulation of intracellular signaling events. Despite these findings, the contribution of PTPs to the regulation of many fundamental physiological processes is not well-characterized. This is the case of angiogenesis, the process whereby new vessels are generated from pre-existing ones. Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors, is known to induce its biological effects mainly by activating VEGFR2 (Vascular endothelial growth factor receptor 2). As angiogenesis is involved in the development of a multitude of pathologies, including tumoral progression, a better characterization of PTPs, which ensure the quality of the angiogenic response by acting together with VEGFR2, is crucial to refine current therapeutic tools. Expression of a PTP called DEP-1 correlates with dephosphorylation of VEGFR2, and contributes to the inhibition of VEGF-induced endothelial cell proliferation at high cell confluence. However, the specific contribution of DEP-1 to the regulation of signaling pathways and biological responses induced by VEGF remained unknown. The research presented in this thesis demonstrates that DEP-1 negatively regulates the tyrosine kinase activity of VEGFR2 by dephosphorylating the specific tyrosine residues Y1054/Y1059 in its activation loop. Consequently, this leads to a global decrease in the phosphorylation of the receptor and to a reduced activation of most of the signaling cascades induced by VEGF, including the mitogenic PLCγ- ERK1/2 pathway. Moreover, despite this negative role, our work reveals for the first time that DEP-1 contributes in a positive way to promote the survival of endothelial cells via the activation of the Src-Gab1-Akt pathway downstream of VEGFR2. This survival function of DEP-1 in endothelial cells is accomplished by the dephosphorylation of the Src inhibitory tyrosine (Y529). During our study, we identified two residues in the carboxy-terminal tail of DEP-1, Y1311 and Y1320, whose phosphorylation is dependent on Src. These two phosphorylated tyrosine residues bind to the SH2 domain of Src, and our work also revealed that mostly Y1320 is required for Src and Akt activation upon VEGF stimulation of endothelial cells. These findings represent a major step forward in our understanding of the molecular mechanisms by which DEP-1 may regulate the VEGF-dependent angiogenic program. Moreover, the discovery of a positive role for DEP-1 in the survival of endothelial cells could lead to the development of new therapeutic approaches to inhibit this specific function of DEP-1 in order to block pathological angiogenesis.

Low affinity Fcg receptor III (FcgRIII, CD16) triggers a variety of cellular events upon binding to the Fc portion of IgG. A real-time flow cytometry method was developed to measure the affinity and kinetics of such low affinity receptor/ligand interactions, which was shown as an easily operated yet powerful tool. Results revealed an unusual temperature dependence of reverse rate of CD16aTM dissociating from IgG. Except for a few studies using mammalian cell CD16s, most kinetics analyses use purified aglycosylated extracellular portion of the molecules, making it impossible to assess the importance of the receptor anchor and glycosylation on ligand binding. We used a micropipette adhesion frequency assay to demonstrate that the anchor length affects the forward rate and affinity of CD16s for IgG in a species specific manner, most likely through conformational changes. Receptor glycosylation dramatically reduced ligand binding by 100 folds. T cell receptor (TCR) is arguably the most important receptor in the adaptive human immune system. Together with coreceptor CD4 or CD8, TCR can discriminate different antigen peptides complexed with major histocompatibility complex (MHC) molecule (pMHC), which differ by as few as only one amino acid, and trigger different T cell responses. When T cell signaling was suppressed, TCR had similar affinity and kinetics for agonist and antagonist pMHC whose binding to CD8 was undetectable. TCR on activated T cell had a higher affinity for pMHCs, suggesting that TCRs organize themselves differently on activated T cells than on naïve T cells. In the absence of inhibitors for signaling, TCR binds agonist pMHC with several orders of magnitude higher affinity than antagonist pMHC. In addition, engagement of TCR by pMHC signals an upregulation of CD8 binding to pMHC, which is much stronger than the TCR-pMHC binding. The transition from weak TCR binding to the strong CD8 binding takes place around 0.75 second after TCR in contact with pMHC and can be reduced by several inhibitors of tyrosine and lipid phosphorylation, membrane rafts, and actin cytoskeleton. These results provide new insights to understanding T cell discrimination.

No description available.

Morphine is a natural opioid which is used in medicine due to his potent analgesic and sedative effects. In the forefront of scientific interest is a chronic usage of opioids which can lead to a development of drug addiction. Morphine role in oxidative stress was described in last years. It was revealed its protective potencial by many studies. However, some studies described its pro-oxidative effect. The aim of this study was to determinate effect of chronic morphine on cell survival after oxidative stress caused by H202 analog - tBHP in the SH-SY5Y neuroblastoma cell line. The results verified morphine protective effect against oxidative stress. The highest protective effect of morphine was achieved in a concetration of 10 µM. It was desribed that morphine can induce activation of mu-opioid (MOR) and Toll-like 4 (TLR4) receptors signalling pathway on molecular level. The aim of this thesis was to evaluate the role of MOR a TLR4 in protective effect of morphine against oxidative stress by two methods. Firstly, it was used tests of oxidative stress on cell viability. The obtained results demonstrated majority role of TLR4 and minory role of MOR. Afterwards, we assesed changes in the expression of MOR a TLR4 after chronic morphine by SDS-PAGE electrophoresis. Results of these experiments did not...